Cargando…

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020

IMPORTANCE: Increasingly, cost-effectiveness analyses are being done to determine the value of rapidly increasing oncology drugs; however, this assumes that these analyses are unbiased. OBJECTIVE: To analyze the characteristics of cost-effectiveness studies and to determine characteristics associate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haslam, Alyson, Lythgoe, Mark P., Greenstreet Akman, Emma, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603079/ https://www.ncbi.nlm.nih.gov/pubmed/34792592 http://dx.doi.org/10.1001/jamanetworkopen.2021.35123

Ejemplares similares

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals
por: Haslam, Alyson, et al.
Publicado: (2023)

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals
por: Buck, Eva, et al.
Publicado: (2023)

Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
por: Haslam, Alyson, et al.
Publicado: (2020)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
por: Benjamin, David J., et al.
Publicado: (2022)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)
por: Jenei, Kristina, et al.
Publicado: (2022)

The frequency of assessment of progression in randomized oncology clinical trials
por: Haslam, Alyson, et al.
Publicado: (2021)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
por: Olivier, Timothée, et al.
Publicado: (2023)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Characteristics of Facebook’s third-party medical fact checkers
por: Haslam, Alyson, et al.
Publicado: (2022)

Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
por: Maeda, Hideki, et al.
Publicado: (2023)

Radiation Oncology Device Approval in the United States and Canada
por: Beers, Craig A, et al.
Publicado: (2019)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use
por: Prasad, Vinay, et al.
Publicado: (2023)

Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020
por: Strahan, Andrea E., et al.
Publicado: (2023)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Assessment of New Molecular Entities Approved for Cancer Treatment in 2020
por: Smith, Claire E. P., et al.
Publicado: (2021)

Characteristics Associated With High-Performing Pediatric Heart Transplant Centers in the United States From 2006 to 2015
por: Singh, Tajinder P., et al.
Publicado: (2020)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

Comparability of Control and Comparison Groups in Studies Assessing Long COVID
por: Haslam, Alyson, et al.
Publicado: (2023)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
por: Lythgoe, Mark P., et al.
Publicado: (2022)

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019
por: Lythgoe, Mark P., et al.
Publicado: (2022)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Oncology approvals in 2020: a year of firsts in the midst of a pandemic
por: Amiri-Kordestani, Laleh, et al.
Publicado: (2021)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Prevalence and Characteristics of Telehealth Utilization in the United States
por: Fischer, Shira H., et al.
Publicado: (2020)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

Medical Reversals in Family Practice: A Review
por: Haslam, Alyson, et al.
Publicado: (2020)

How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature
por: Haslam, Alyson, et al.
Publicado: (2022)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)

The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review
por: Bhatt, Anjali, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_th9i563rpf8as1h3qkeq5svp5i